Skip to Main Content

We are a few days away from the start of the biggest and most important biotech business meeting of the year — the J.P. Morgan Healthcare Conference in San Francisco. If you sit through enough presentations at J.P. Morgan, you start to get buzz-phrase fatigue. Seemingly everything is a “transformational” “holy grail” of a “game-changer,” endorsed by “key opinion leaders” with “clinically meaningful” “optionality.”

But it doesn’t have to be that way.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED